Curcumin as a Holistic Treatment for Tau Pathology

Research output: Contribution to journalArticlepeer-review

Standard Standard

Curcumin as a Holistic Treatment for Tau Pathology. / Sivanantharajah, Lovesha; Mudher, Amritpal.
In: Frontiers in Pharmacology, Vol. 13, 903119, 19.05.2022.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

APA

CBE

MLA

VancouverVancouver

Sivanantharajah L, Mudher A. Curcumin as a Holistic Treatment for Tau Pathology. Frontiers in Pharmacology. 2022 May 19;13:903119. doi: 10.3389/fphar.2022.903119

Author

Sivanantharajah, Lovesha ; Mudher, Amritpal. / Curcumin as a Holistic Treatment for Tau Pathology. In: Frontiers in Pharmacology. 2022 ; Vol. 13.

RIS

TY - JOUR

T1 - Curcumin as a Holistic Treatment for Tau Pathology

AU - Sivanantharajah, Lovesha

AU - Mudher, Amritpal

PY - 2022/5/19

Y1 - 2022/5/19

N2 - Global forecasts for prevalence of Alzheimer's Disease (AD) estimate that 152.8 million people will have dementia in 2050, a sharp rise from 57.4 million in 2019 (GBD 2019). This rise can be attributable to increases in population growth and aging, but in the absence of disease-modifying therapies it poses a huge societal challenge that must be addressed urgently. One way to combat this challenge is to explore the utility of holistic treatments that may protect against AD, including traditional herbs, spices and other nutraceuticals that are pharmacologically safe, inexpensive and readily available. In this light, the spice turmeric, and its active ingredient curcumin, has been investigated as a potential holistic treatment for AD over the past 2 decades; however, promising results with animal studies have not translated to success in clinical trials. One issue is that most animal models examining the effects of curcumin and curcumin derivatives in AD have been done with a focus at ameliorating amyloid pathology. Due to the limited success of Amyloid-β-based drugs in recent clinical trials, tau-focused therapeutics provide a promising alternative. In this article, we aim to provide a clearer picture of what is currently known about the effectiveness of curcumin and curcumin derivatives to ameliorate tau pathology. Tau focused studies may help inform more successful clinical studies by placing greater emphasis on the development and optimised delivery of curcumin derivatives that more effectively target tau pathology.

AB - Global forecasts for prevalence of Alzheimer's Disease (AD) estimate that 152.8 million people will have dementia in 2050, a sharp rise from 57.4 million in 2019 (GBD 2019). This rise can be attributable to increases in population growth and aging, but in the absence of disease-modifying therapies it poses a huge societal challenge that must be addressed urgently. One way to combat this challenge is to explore the utility of holistic treatments that may protect against AD, including traditional herbs, spices and other nutraceuticals that are pharmacologically safe, inexpensive and readily available. In this light, the spice turmeric, and its active ingredient curcumin, has been investigated as a potential holistic treatment for AD over the past 2 decades; however, promising results with animal studies have not translated to success in clinical trials. One issue is that most animal models examining the effects of curcumin and curcumin derivatives in AD have been done with a focus at ameliorating amyloid pathology. Due to the limited success of Amyloid-β-based drugs in recent clinical trials, tau-focused therapeutics provide a promising alternative. In this article, we aim to provide a clearer picture of what is currently known about the effectiveness of curcumin and curcumin derivatives to ameliorate tau pathology. Tau focused studies may help inform more successful clinical studies by placing greater emphasis on the development and optimised delivery of curcumin derivatives that more effectively target tau pathology.

KW - Alzheheimer’s disease; animal models; curcumin; holistic medicine; tauopathy; turmeric (Curcuma longa L)

U2 - 10.3389/fphar.2022.903119

DO - 10.3389/fphar.2022.903119

M3 - Article

C2 - 35662729

VL - 13

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 903119

ER -